loading page

A Pilot Study of Plasma Microbial Cell-Free DNA Following Chimeric Antigen Receptor T Cell Therapy in Pediatric Patients with Relapsed/Refractory Leukemia
  • +3
  • Catherine Aftandilian,
  • Xue Rachel Bito,
  • David Berman,
  • Amy Zhang,
  • Radha Duttagupta,
  • Kara Davis
Catherine Aftandilian
Stanford University

Corresponding Author:[email protected]

Author Profile
Xue Rachel Bito
Children's Hospital Los Angeles Children's Center for Cancer and Blood Diseases
Author Profile
David Berman
Karius Inc
Author Profile
Amy Zhang
Stanford University Department of Medicine
Author Profile
Radha Duttagupta
Nucleix Ltd
Author Profile
Kara Davis
Stanford University
Author Profile


Chimeric antigen receptor (CAR) T cell therapy is a promising treatment for pediatric patients with relapsed or refractory B cell acute lymphoblastic leukemia (R/R B ALL). Cytokine release syndrome (CRS) is a common toxicity after CAR T cell therapy and fever is often the first symptom. Differentiating CRS from infection after CAR T cell therapy can be challenging. Plasma microbial cell free DNA (mcfDNA) is a novel diagnostic tool which allows for qualitative and quantitative assessment of over 1,000 organisms. This pilot study sought to characterize mcfDNA results in pediatric patients with R/R B ALL in the first two months after CAR T cell therapy.